Published on 6 Jun 2016
Valeant Pharmaceuticals is set to release results before the bell Tuesday. Analysts are anticipating the Botox maker to report adjusted earnings of $1.36 a share, that's down $1 from a year ago. Revenue estimates for this quarter are expected to grow about 8.7% to about $2.4 billion. Tuesday is Valeant's second quarterly report since its pricing and compliance scandals were revealed. The Fill or Kill team will be keeping a close eye on whether or not Valeant will beat top and bottom line estimates.. and if there is any further information on how the drug maker plans to reduce its debt.